MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MannKind Corp (MNKD) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown strong revenue growth, significant risks related to its key product Tyvaso DPI, declining net income, bearish technical indicators, and lack of strong trading signals make it prudent to hold off on investing until more clarity emerges on its future prospects.
The technical indicators for MNKD are bearish. The MACD histogram is negative and contracting, RSI is extremely oversold at 7.496, and the moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 2.321, indicating potential further downside.
Record Q4 2025 revenue of $112 million, a 46% YoY increase.
Acquisition of SC Pharmaceuticals to enhance its product line.
Positive sentiment around Furoscix and Afrezza as potential growth drivers.
Significant risks to Tyvaso DPI royalties due to competition from United Therapeutics' soft mist inhaler.
Declining net income (-314.87% YoY) and EPS (-266.67% YoY) despite revenue growth.
Hedge funds are selling heavily, with a 337.78% increase in selling activity last quarter.
Analysts have lowered price targets significantly, with RBC Capital downgrading the stock to Sector Perform.
In Q4 2025, MannKind reported a 46% YoY revenue increase to $111.96 million. However, net income dropped sharply by -314.87% YoY to -$15.95 million, and EPS declined by -266.67% YoY to -$0.05. Gross margin also fell by -6.81% YoY to 71.82%. While revenue growth is strong, profitability metrics are deteriorating.
Analysts have mixed views. H.C. Wainwright and Wells Fargo maintain Buy and Overweight ratings, citing favorable risk/reward on Furoscix and Afrezza. However, RBC Capital downgraded the stock to Sector Perform, citing significant risks to Tyvaso DPI royalties. Price targets have been lowered across the board, reflecting cautious sentiment.
